Correlation of Smad4 Status With Outcomes in Patients Receiving Erlotinib Combined With Adjuvant Chemoradiation and Chemotherapy After Resection for Pancreatic Adenocarcinoma

Podobne zapisy

• Phase 2 Study of Erlotinib Combined With Adjuvant Chemoradiation and Chemotherapy in Patients With Resectable Pancreatic Cancer
  od: Herman, Joseph M., i wsp.
  Wydane: (2013)
• Adjuvant Chemoradiation Therapy for Adenocarcinoma of the Distal Pancreas
  od: Redmond, Kristin J., i wsp.
  Wydane: (2010)
• Smad4 Loss Correlates with Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation
  od: Herman, Joseph M., i wsp.
  Wydane: (2018)
• Adjuvant chemoradiation versus surgery alone for adenocarcinoma of the ampulla of Vater
  od: Zhou, Jessica, i wsp.
  Wydane: (2009)
• A Tolerability and Pharmacokinetic Study of Adjuvant Erlotinib and Capecitabine with Concurrent Radiation in Resected Pancreatic Cancer
  od: Ma, Wen Wee, i wsp.
  Wydane: (2010)